Skip to main content
SpringerLink
Log in

Adalimumab/betamethasone-dipropionate/calcipotriol

Lack of efficacy and paradoxical hidradenitis suppurativa: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Martora F, et al. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on 'Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab'. Clinical and Experimental Dermatology 48: 701-703, No. 6, et al. Jun 2023. Available from: URL: http://doi.org/10.1093/ced/llad082

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/betamethasone-dipropionate/calcipotriol. Reactions Weekly 1965, 22 (2023). https://doi.org/10.1007/s40278-023-42990-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-42990-2

Search

Navigation